Atmosphere-ph.ru

Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru

ИНТЕРНЕТ-МАГАЗИН

Телефон издательства

Лечебное дело
2020 / N 1

Фенофибрат при лечении больных с гипертриглицеридемиями и атеросклерозом: новые данные
А.В. Сусеков

Список литературы

1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoğlu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoprotein cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2017 Aug;38(32):2459-72.
2. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, van de Sluis MRTB, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2020 Feb 13. pii: ehz962.
3. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019 Nov;290:140-205.
4. Grundy SM, Stone NJ, Bailey C, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019 Jun;139(25):e1082-143.
5. Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients 2013 Mar;5(3):981-1001.
6. Hassing HC, Surendran RP, Mooij HL, Stroes ES, Nieuwdorp M, Dallinga-Thie GM. Pathophysiology of hypertriglyceridemia. Biochimica et Biophysica Acta 2012 May;182(5):826-32.
7. Chapman MJ, Ginsberg HN, Amarenco P, Felicita Andreotti, Jan Borén, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen AT, Watts GF; European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 2011 Jun;32(11):1345-61.
8. Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, Borén J, Bruckert E, Catapano AL, Descamps OS, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AFH, Stroes E, Taskinen MR, Tybjærg-Hansen A, Watts GF, Wiklund O; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for deﬁnition, diagnosis, and management. The Lancet. Diabetes & Endocrinology 2014 Aug;2(8):655-66.
9. Rashid N, Sharma PP, Scott RD, Lin KJ, Toth PP. Severe hypertriglyceridemia and factors associated with acute pancreatitis in an integrated health care system. Journal of Clinical Lipidology 2016 Jul-Aug;10(4):880-90.
10. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. Journal of Lipid Research 1993 Oct;34(10):1637-59.
11. Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation 1965 Mar;31:321-7.
12. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet 2010 Nov;376(9753):1670-81.
13. Cholesterol Treatment Trialists (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet 2012 Aug;380(9841):581-90.
14. Cholesterol Treatment Trialists (CTT) Collaborators. Fulcher J, O’Connel R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, Rosa JL, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomized trials. The Lancet 2015 Apr;385(9976):1397-405.
15. Зубарева М.Ю., Сусеков А.В. Программа снижения остаточного (резидуального) сосудистого риска: проект R3i (the Residual Risk Reduction Initiative). Часть I. Факторы остаточного риска. Кардиология 2010;8:76-83.
16. Зубарева М.Ю., Сусеков А.В. Программа снижения остаточного (резидуального) риска развития сосудистых осложнений: проект R3i (the Residual Risk Reduction Initiative). Часть II. Методы коррекции. Кардиология 2010;9:64-70.
17. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. The American Journal of Cardiology 2008 Nov;102(10 Suppl):1K-34K.
18. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im KA, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. The New England Journal of Medicine 2015 Jun;372(25):2387-97.
19. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. The New England Journal of Medicine 2017 May 4;376(18):1713-22.
20. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg G; ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet. Diabetes & Endocrinology 2019 Aug;7(8):P618-28.
21. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson T, Ketchum SV, Doyle RT, Juliana RA, Jiao L, Granovits K, Tardif JC, Ballantyne SM. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. The New England Journal of Medicine 2019 Jan;380(1):11-22.
22. Сусеков А.В. Холестерин липопротеинов низкой плотности (ХС-ЛНП) и ремнантный холестерин неЛВП: нужна ли рокировка для оценки сердечно-сосудистого риска? Медицинский Совет 2013;9:50-5.
23. Sniderman AD, Williams K, Contoins JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B as a markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes 2011;4(3):337-45.
24. Varbo A, Benn M, Tybjarg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. Journal of the American College of Cardiology 2013 Jan;61(4):427-36.
25. Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, Di Biase M, Brunetti ND. Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vascular Health and Risk Management 2017 Feb;13:29-41.
26. Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vascular Health and Risk Management 2008;4(5):991-1000.
27. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Current Atherosclerosis Reports 2001 Jan;3(1):83-92.
28. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998 Nov;98(19):2088-93.
29. Chapman MJ. Fibrates: therapeutic review. The British Journal of Diabetes & Vascular Disease 2006 Jan;6(1):11-9.
30. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine 2001 Jan;7(1):53-8.
31. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M; FIELD Study Investigators. Effects of long-term fenofibrate therapy on ardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. The Lancet 2005 Nov;366(9500):1849-61.
32. Sahebkar A, Simental-Mendía LE, Watts GF, Serban MC, Banach M. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Medicine 2017 Feb;15(1):22.
33. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology 2002 May;22(5):717-26.
34. Zambon A, Gervois P, Pauletto P, Fruchart JC, Bart Staels B. Modulation of hepatic inﬂammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arteriosclerosis, Thrombosis and Vascular Biology 2006 May;26(5):977-86.
35. Rosenson RS, Kuskin AL, Wolff DA, Helenowski IB, Rademaker AW. Fenoﬁbrate reduces fasting and postprandial inﬂammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis 2008 Jun;198(2):381-8.
36. Liamis G, Bairaktari ET, Elisaf MS. Effect of fenoﬁbrate on serum uric acid levels. American Journal of Kidney Diseases 1999 Sep;34(3):594.
37. Keating GM, Ormrod D. Micronised fenoﬁbrate: an updated review of its clinical efﬁcacy in the management of dyslipidaemia. Drugs 2002;62(13):1909-44.
38. Troutt JS, Alborn WE, Cao G, Konrad RJ. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. Journal of Lipid Research 2010 Feb;51(2):345-51.
39. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid-lowering therapy in type 2 diabetes mellitus. The New England Journal of Medicine 2010 Apr;362(17):1563-74.
40. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D’Emden MC, Laakso M, Baker JR, Keech AC; FIELD Study Investigators. Effect of fenoﬁbrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespeciﬁed analysis of a randomised controlled trial. The Lancet 2009 May;373:1780-88.
41. ACCORD Study Group; ACСORD Eye Study Group; Chew E, Ambrosius W, Davis MD, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. The New England Journal of Medicine 2010 Jul;363(3):233-44.
42. Сусеков А.В., Хохлова Н.В. Перспективы использования фенофибрата у больных с сахарным диабетом 2-го типа: что нового после исследования ACCORD? Кардиология 2011;51(9):68-74.
43. Сусеков А.В. Дериваты фиброевой кислоты: фокус на фенофибрат. Кардиология 2013;53(1):79-86.
44. Downing NS, AB, Cheng T, Harlan M, Krumholz HM, Shah ND, Ross JS. Descriptions and interpretation of the ACCORD-lipid trial in news and biomedical literature: a cross-sectional analysis. AMA Internal Medicine 2014 Jul;174(7):1176-82.
45. Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Ridker PM. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. American Heart Journal 2018 Dec;206:80-93.
46. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. The Lancet 2010 May;375(9729):1875-84.
47. Lee M, Savera L, Towfighic A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011 Aug;217(2):492-8.
48. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia proﬁle: a systematic review and meta-analysis. Journal of Cardiovascular Pharmacology 2011 Feb;57(2):267-72.
49. Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O’Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg YL, Rosenberg Y, Byington RP; ACCORDION Study Investigators Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiology 2017 Apr;2(4):370-80.
50. ACCORDION: the ACCORD follow-on study. Protocol (March 18, 2011–Version G). Confidential. Available from: https://biolincc.nhlbi.nih.gov/media/studies/accord/ACCORDION_Protocol.pdf Accessed 2020 Jun 18.
51. Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovascular Diabetology 2020 Mar;19(1):28.
52. Farnier M, Freeman M, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, Gumbiner B; Ezetimibe Study Group Efficacy and safety of coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidemia. European Heart Journal 2005 May;26(9):897-905.
53. Koh KK, Oh PC, Sakuma I, Lee Y, Han SH, Shin EK. Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia. International Journal of Cardiology 2016 Oct; 221:342-6.
54. Franssen R, Vergeer M, Stroes ESG, Kastelein JJP. Combination statin-fibrate therapy: safety aspects. Diabetes, Obesity & Metabolism 2009 Feb;11(2):89-94.
55. Guo J, Meng F, Ma N, Chunhua Li, Ding Z, Wang, Hou R, Qin Y. Meta-analysis of safety of coadministration of statin with fenofibrate in patients with combined hyperlipidemia. The American Journal of Cardiology 2012 Nov;110(9):1296-301.
56. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Yannicelli HD, Anderson JL. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. Journal of the American College of Cardiology 2006 Jul;48(2):396-401.
57. Kayikçioğlu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. The American Journal of Cardiology 1999 Apr;83(7):1135-7, A9.
58. Sahebkar A, Serban MC, Mikhailidis DP, Toth PP, Muntner P, Ursoniu S, Mosterou S, Glasser S, Martin SS, Jones SR, Rizzo M, Rysz J, Sniderman AD, Pencina MJ, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: a systematic review and meta-analysis. Pharmacological Research 2016 Jan;103:236-52.
59. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). The American Journal of Cardiology 2005 Feb;95(4):462-8.
60. Oikawa S, Yamashita S, Nakaya N, Sasaki J, Kono S; Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis and Thrombosis 2017 Jan;24(1):77-94.

References

1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoğlu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoprotein cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2017 Aug;38(32):2459-72.
2. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, van de Sluis MRTB, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2020 Feb 13. pii: ehz962.
3. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019 Nov;290:140-205.
4. Grundy SM, Stone NJ, Bailey C, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019 Jun;139(25):e1082-143.
5. Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients 2013 Mar;5(3):981-1001.
6. Hassing HC, Surendran RP, Mooij HL, Stroes ES, Nieuwdorp M, Dallinga-Thie GM. Pathophysiology of hypertriglyceridemia. Biochimica et Biophysica Acta 2012 May;182(5):826-32.
7. Chapman MJ, Ginsberg HN, Amarenco P, Felicita Andreotti, Jan Borén, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen AT, Watts GF; European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 2011 Jun;32(11):1345-61.
8. Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, Borén J, Bruckert E, Catapano AL, Descamps OS, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AFH, Stroes E, Taskinen MR, Tybjærg-Hansen A, Watts GF, Wiklund O; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for deﬁnition, diagnosis, and management. The Lancet. Diabetes & Endocrinology 2014 Aug;2(8):655-66.
9. Rashid N, Sharma PP, Scott RD, Lin KJ, Toth PP. Severe hypertriglyceridemia and factors associated with acute pancreatitis in an integrated health care system. Journal of Clinical Lipidology 2016 Jul-Aug;10(4):880-90.
10. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. Journal of Lipid Research 1993 Oct;34(10):1637-59.
11. Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation 1965 Mar;31:321-7.
12. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet 2010 Nov;376(9753):1670-81.
13. Cholesterol Treatment Trialists (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet 2012 Aug;380(9841):581-90.
14. Cholesterol Treatment Trialists (CTT) Collaborators. Fulcher J, O’Connel R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, Rosa JL, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomized trials. The Lancet 2015 Apr;385(9976):1397-405.
15. Zubareva MYu, Susekov AV. Reducing the residual risk of vascular complications: R3i project (the Residential Risk Reduction Initiative). Part I. Residual risk factors. Kardiologiia 2010;8:76-83 (In Russian).
16. Zubareva MYu, Susekov AV. Program for reducing the residual risk of vascular complications: R3i project (the Residential Risk Reduction Initiative). Part II. Correction methods. Kardiologiia 2010;9:64-70 (In Russian).
17. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. The American Journal of Cardiology 2008 Nov;102(10 Suppl):1K-34K.
18. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im KA, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. The New England Journal of Medicine 2015 Jun;372(25):2387-97.
19. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. The New England Journal of Medicine 2017 May;376(18):1713-22.
20. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg G; ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet. Diabetes & Endocrinology 2019 Aug;7(8):P618-28.
21. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson T, Ketchum SV, Doyle RT, Juliana RA, Jiao L, Granovits K, Tardif JC, Ballantyne SM. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. The New England Journal of Medicine 2019 Jan;380(1):11-22.
22. Susekov AV. Low-density lipoprotein cholesterol (LDL-C) and remnant non-HDL cholesterol: any reason to change the order when assessing cardiovascular risk? Medical Council 2013;9:50-5 (In Russian).
23. Sniderman AD, Williams K, Contoins JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B as a markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes 2011;4(3):337-45.
24. Varbo A, Benn M, Tybjarg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. Journal of the American College of Cardiology 2013 Jan;61(4):427-36.
25. Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, Di Biase M, Brunetti ND. Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vascular Health and Risk Management 2017 Feb;13:29-41.
26. Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vascular Health and Risk Management 2008;4(5):991-1000.
27. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Current Atherosclerosis Reports 2001 Jan;3(1):83-92.
28. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998 Nov;98(19):2088-93.
29. Chapman MJ. Fibrates: therapeutic review. The British Journal of Diabetes & Vascular Disease 2006 Jan;6(1):11-9.
30. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine 2001 Jan;7(1):53-8.
31. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M; FIELD Study Investigators. Effects of long-term fenofibrate therapy on ardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. The Lancet 2005 Nov;366(9500):1849-61.
32. Sahebkar A, Simental-Mendía LE, Watts GF, Serban MC, Banach M. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Medicine 2017 Feb;15(1):22.
33. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology 2002 May;22(5):717-26.
34. Zambon A, Gervois P, Pauletto P, Fruchart JC, Bart Staels B. Modulation of hepatic inﬂammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arteriosclerosis, Thrombosis and Vascular Biology 2006 May;26(5):977-86.
35. Rosenson RS, Kuskin AL, Wolff DA, Helenowski IB, Rademaker AW. Fenoﬁbrate reduces fasting and postprandial inﬂammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis 2008 Jun;198(2):381-8.
36. Liamis G, Bairaktari ET, Elisaf MS. Effect of fenoﬁbrate on serum uric acid levels. American Journal of Kidney Diseases 1999 Sep;34(3):594.
37. Keating GM, Ormrod D. Micronised fenoﬁbrate: an updated review of its clinical efﬁcacy in the management of dyslipidaemia. Drugs 2002;62(13):1909-44.
38. Troutt JS, Alborn WE, Cao G, Konrad RJ. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. Journal of Lipid Research 2010 Feb;51(2):345-51.
39. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid-lowering therapy in type 2 diabetes mellitus. The New England Journal of Medicine 2010 Apr;362(17):1563-74.
40. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D’Emden MC, Laakso M, Baker JR, Keech AC; FIELD Study Investigators. Effect of fenoﬁbrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespeciﬁed analysis of a randomised controlled trial. The Lancet 2009 May;373:1780-88.
41. ACCORD Study Group; ACСORD Eye Study Group; Chew E, Ambrosius W, Davis MD, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. The New England Journal of Medicine 2010 Jul;363(3):233-44.
42. Susekov AV, Khokhlova NV. Fenofibrate in patients with type 2 diabetes: what is new after ACCORD study? Kardiologiia 2011;51(9):68-74 (In Russian).
43. Susekov AV. Fibric acid derivatives: focus on the fenofibrate. Kardiologiia 2013;53(1):79-86 (In Russian).
44. Downing NS, AB, Cheng T, Harlan M, Krumholz HM, Shah ND, Ross JS. Descriptions and interpretation of the ACCORD-lipid trial in news and biomedical literature: a cross-sectional analysis. AMA Internal Medicine 2014 Jul;174(7):1176-82.
45. Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Ridker PM. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. American Heart Journal 2018 Dec;206:80-93.
46. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. The Lancet 2010 May;375(9729):1875-84.
47. Lee M, Savera L, Towfighic A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011 Aug;217(2):492-8.
48. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia proﬁle: a systematic review and meta-analysis. Journal of Cardiovascular Pharmacology 2011 Feb;57(2):267-72.
49. Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O’Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg YL, Rosenberg Y, Byington RP; ACCORDION Study Investigators. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiology 2017 Apr;2(4):370-80.
50. ACCORDION: the ACCORD follow-on study. Protocol (March 18, 2011–Version G). Confidential. Available from: https://biolincc.nhlbi.nih.gov/media/studies/accord/ACCORDION_Protocol.pdf Accessed 2020 Jun 18.
51. Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovascular Diabetology 2020 Mar;19(1):28.
52. Farnier M, Freeman M, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, Gumbiner B; Ezetimibe Study Group Efficacy and safety of coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidemia. European Heart Journal 2005 May;26(9):897-905.
53. Koh KK, Oh PC, Sakuma I, Lee Y, Han SH, Shin EK. Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia. International Journal of Cardiology 2016 Oct; 221:342-6.
54. Franssen R, Vergeer M, Stroes ESG, Kastelein JJP. Combination statin-fibrate therapy: safety aspects. Diabetes, Obesity & Metabolism 2009 Feb;11(2):89-94.
55. Guo J, Meng F, Ma N, Chunhua Li, Ding Z, Wang, Hou R, Qin Y. Meta-analysis of safety of coadministration of statin with fenofibrate in patients with combined hyperlipidemia. The American Journal of Cardiology 2012 Nov;110(9):1296-301.
56. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Yannicelli HD, Anderson JL. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. Journal of the American College of Cardiology 2006 Jul;48(2):396-401.
57. Kayikçioğlu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. The American Journal of Cardiology 1999 Apr;83(7):1135-7, A9.
58. Sahebkar A, Serban MC, Mikhailidis DP, Toth PP, Muntner P, Ursoniu S, Mosterou S, Glasser S, Martin SS, Jones SR, Rizzo M, Rysz J, Sniderman AD, Pencina MJ, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: a systematic review and meta-analysis. Pharmacological Research 2016 Jan;103:236-52.
59. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). The American Journal of Cardiology 2005 Feb;95(4):462-8.
60. Oikawa S, Yamashita S, Nakaya N, Sasaki J, Kono S; Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. Journal of Atherosclerosis and Thrombosis 2017 Jan;24(1):77-94.

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]